Medtech Industry Establishes Foundation for Clinical Trials with Veeva MedTech

Yahoo

a day ago

More than 50 medtech companies, including 11 of the top 20, have adopted Veeva clinical applications for greater efficiency and speed
PLEASANTON, Calif., June 11, 2025 /PRNewswire/ -- Veeva Systems (NYSE: VEEV) today announced that more than 50 medtech companies, including 11 of the top 20 medtechs and seven of the top 10 medtech clinical research organizations (CROs), have selected Veeva Clinical Platform applications to simplify and streamline medical device and diagnostics studies. With increasing regulatory requirements and evolving markets, medtech companies are moving away from siloed legacy solutions to modern connected applications from Veeva MedTech.
With a growing number of medical device and diagnostic clinical trials executed on Veeva Clinical applications, companies can gain the scalability to grow while maintaining compliance with local, regional, and global regulations. Medtechs of all sizes use Veeva to drive improvements, with customers achieving 50% faster study build times with Veeva EDC and 80% reductions in duplicate trial documents with Veeva eTMF.
"It's exciting to partner with the industry as it moves to Veeva MedTech for a complete and connected medical device and diagnostics clinical trials infrastructure," said Kevin Liang, vice president of clinical strategy at Veeva MedTech. "We're working with leading medtechs to advance study execution, collaboration, and innovation to bring life-changing products to patients faster."
What the medtech clinical industry is saying about Veeva:
"With Veeva EDC, we've partnered closely with their team to enhance the global library and develop reusable standards.," said Leianne Ebert, head of clinical data operations at Alcon. "We focused on getting standards right, and that commitment drove 50% standardization in one year, boosting our compliance with our global library."
"Veeva allows us to collect study data consistently in a manner that regulatory agencies will accept," said Kimberly Dorsch, vice president of global clinical affairs at LifeNet Health. "Whether it's a registry study or an IDE/IND study supporting a PMA/BLA, the data's going to be collected the exact same way and in a compliant manner."
"Since implementing Veeva eTMF, we've reduced our quality control time by over 90% and decreased our document creation times significantly," said Matt Christensen, senior vice president, global clinical and medical affairs at Smith+Nephew.
Learn more about Veeva Clinical Platform applications for medtech at veeva.com/MedTechClinical.
About Veeva SystemsVeeva is the global leader in cloud software for the life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 1,000 customers, ranging from the world's largest biopharmaceutical companies to emerging biotechs. As a Public Benefit Corporation, Veeva is committed to balancing the interests of all stakeholders, including customers, employees, shareholders, and the industries it serves. For more information, visit veeva.com.
Veeva Forward-looking StatementsThis release contains forward-looking statements regarding Veeva's products and services and the expected results or benefits from use of our products and services. These statements are based on our current expectations. Actual results could differ materially from those provided in this release and we have no obligation to update such statements. There are numerous risks that have the potential to negatively impact our results, including the risks and uncertainties disclosed in our filing on Form 10-Q for the period ended April 30, 2025, which you can find here (a summary of risks which may impact our business can be found on pages 32 and 33), and in our subsequent SEC filings, which you can access at sec.gov.
Contact:Deivis MercadoVeeva [e-mail]
View original content to download multimedia:https://www.prnewswire.com/news-releases/medtech-industry-establishes-foundation-for-clinical-trials-with-veeva-medtech-302477387.html
SOURCE Veeva Systems